AZD8330 First Time in Man in Patients With Advanced Malignancies

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Phase 1

AstraZeneca